

27 January 2023

IXICO plc
("IXICO" or the "Company")

Results of AGM

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

	RESOLUTION	VOTES FOR	%	VOTES AGAINST	%	VOTES TOTAL	% ISC VOTED	VOTES WITHHELD
1	Reports and Accounts	26,812,002	99.96%	11,472	0.04%	26,823,474	55.48	9,231
2a	Re-election of Giulio Cerroni	26,821,033	99.96%	11,372	0.04%	26,832,405	55.49	300
2b	Election of Kate Rogers	26,675,515	99.95%	12,670	0.05%	26,688,185	55.20	144,520
3	Re-appointment of Auditors	26,808,776	99.94%	16,198	0.06%	26,824,974	55.48	7,731
4	Allotment of Securities	26,812,002	99.93%	19,681	0.07%	26,831,683	55.49	1,022
5	* Disapply Pre-Emption Provisions	26,674,807	99.92%	22,559	0.08%	26,697,366	55.22	135,339

* Special Resolution

Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation of the proportion of the votes 'for' and 'against' a resolution.

For further information please contact:

IXICO plc
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer

+44 (0)20 3763 7499

Cenkos Securities PLC (Nominated adviser and sole broker)
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Tamar Cranford-Smith (Sales)

+44 (0)20 7397 8900

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough machine learning AI data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGNKOBPBBKDCDB